Mark Your Calendar for BPI US West 2025!
March 18-21, 2025San Diego Convention Center Bijan BoldajipourVice President Discovery and Development at Lyell Immunopharma, Inc., USASpeaker
Profile
| Bijan Boldajipour oversees the Discovery and Development Team at Lyell that develops novel chimeric antigen receptor (CAR), TCR and tumor-infiltrating lymphocyte (TIL) products for the treatment of cancer. His team investigates how T cells can be genetically engineered to increase their anti-tumor potential and how to make them resistant to the suppressive tumor microenvironment. He brings 13 years of academic and industry experience, researching mechanisms of T cell dysfunction in tumors at UCSF and developing adoptive T cell therapies at Pfizer and Kite Pharma. |
Agenda Sessions
Preclinical Development of LYL119, a ROR1-Targeted CAR T-cell Product Incorporating Four Novel T-Cell Reprogramming Technologies to Overcome Barriers to Effective Cell Therapy for Solid
, 11:00amView Session